Skip to main content
SYRE logo

SYRE · Spyre Therapeutics, Inc. · Holdings

Track SYRE — free
$99.75 +0.71 (+0.71%)
Market Cap
$8.72B
Shares
88.17M
Volume · Oct 28 722.56K Avg daily vol (3M) 1.22M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 274
Total Value: $8,620,669,316
Total Shares: 97,099,560
Showing 1–100 of 282 holdings by value · page 1 of 3

Institutional Ownership Trend

13 quarters

Holder Concentration

Across 267 13F filers
Top Holder
13.5%
Sep 2023 → Jun 2026 · range 13.5% – 24.6%
of institutional value
Top 5
33.1%
Sep 2023 → Jun 2026 · range 33.1% – 62.0%
of institutional value
Top 10
48.9%
Sep 2023 → Jun 2026 · range 48.9% – 87.4%
of institutional value
HHI
397
Sep 2023 → Jun 2026 · range 397 – 1,122
Broadly held

Who Holds SYRE

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 265 filers, like-for-like change +15.9%; actively managed books +12.6%; index-like books +30.2%.

Holder type Share Filers Change
Registered adviser 48.8% 133 +7.5%
Exempt adviser 1.1% 3 +571.6%
Adviser 5.7% 10 +41.0%
Bank 8.3% 16 +25.5%
Insurer 0.2% 2 +130.4%
Benefit plan 0.2% 6 +36.8%
Non-US 0.9% 9 +188.8%
Holding company 24.3% 10 +18.6%
Broker-dealer 0.0% 0 -100.0%
Unknown 10.6% 76 +17.2%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-03-31 13F and 1 holder with no observed 2026-06-30 13F. Compared across CIK changes: JANUS HENDERSON GROUP PLC continues as Jupiter Topco LLC.

Conviction and Crowding

265 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
12
4.53% of filers hold it in their top 10
Mar 31, 2026: 10
Holders above 5%
7
median weight 0.008%
Mar 31, 2026: 5
Crowding
—
holders exceed shares outstanding: 13F filers report more shares than the cover-page count, which predates an issuance, is misstated, or misses shares lent and reported twice
Private-fund advisers
—
of shares outstanding
Institutional ownership
—
holders exceed shares outstanding: 13F filers report more shares than the cover-page count, which predates an issuance, is misstated, or misses shares lent and reported twice
Top 10 holders
49.2%
of 13F shares, Herfindahl 0.040
Active holders
+12.6%
like-for-like share change of active filers
5% stakes on record
3
1 13D, 2 13G (2 institutional, 0 passive, 0 exempt)
How long holders have held it value-weighted 8.2 quarters
Under 1 year 20.9% 1 to 3 years 62.4% 3 years or more 16.8% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net sellers of $275,275,767 (4 buying, 3 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$39.69
estimated per share
Mar 31, 2026: $25.30
Quarter-end price
$88.78
implied by 13F values
Estimated gain or loss
+123.7%
price against the estimated cost
Estimated at a loss
0.000%
of costed 13F value

Estimated cost covers 67.9% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies SYRE's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 ORKA Oruka Therapeutics, Inc. 28
2 DNTH Dianthus Therapeutics, Inc. 26
3 TNGX Tango Therapeutics, Inc. 23
4 ELVN Enliven Therapeutics, Inc. 21
5 EWTX Edgewise Therapeutics, Inc. 18
6 COGT Cogent Biosciences, Inc. 23
7 ERAS Erasca, Inc. 18
8 CYTK Cytokinetics Inc 25
9 DMRA Damora Therapeutics, Inc. 13
10 PRAX Praxis Precision Medicines, Inc. 19

Shareholder Targets

13F filers that own its peers but not SYRE, quarter ended Jun 30, 2026

Found through its holder-overlap peers: ORKA, DNTH, TNGX, ELVN, EWTX, COGT, ERAS, CYTK, DMRA, PRAX, XENE, AMLX, DFTX, PTGX, RACC, SVRA, IMVT, RVMD, KOD, MBX. 898 filers in all.

# Filer In peers
1 BAKER BROS. ADVISORS LP Registered adviser, Concentrated $4,045,707,377 10 held
2 FARALLON CAPITAL MANAGEMENT LLC Registered adviser, Diversified active $3,925,274,340 5 held
3 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $2,926,285,529 11 held
4 Darwin Global Management, Ltd. Exempt adviser, Concentrated $1,990,753,064 1 held
5 Avoro Capital Advisors LLC Registered adviser, Concentrated $1,641,439,814 5 held
6 Nextech Invest, Ltd. Exempt adviser, Concentrated $1,423,531,573 1 held
7 DEERFIELD MANAGEMENT COMPANY, L.P. Registered adviser, Concentrated $1,386,032,725 7 held
8 Fairmount Funds Management LLC Registered adviser, Concentrated $1,133,736,501 5 held
9 Deep Track Capital, LP Adviser, Diversified active $1,047,953,526 8 held
10 Frazier Life Sciences Management, L.P. Registered adviser, Concentrated $983,427,101 4 held

Fund Ownership of SYRE by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 15.38% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 2.97% 2,621,253
Index ETFs 12.41% 10,942,997
Active ETFs 0.11% 95,963
Active funds 21.09% 18,597,503
Unclassified 0.35% 307,635
All registered funds 36.93% 32,565,351
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Showing 100 of 282
Export CSV
Holder Value (USD) % of 13F Shares Open

Showing the top 100 of 282 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1636282 CUSIP 00773J202 13F (30d) 27 filings 27 filers Visit website Investor relations